Alpha Modus Holdings Inc. Class A Common Stock (NASDAQ:AMOD)

Home >> Stock >> Alpha Modus Holdings Inc. Class A Common Stock >> Ratio

Blog+More

Most agile lean enterprises often choose to cut costs strategically to make their respective business models fit for growth.

Daphne Basel

2020-10-27 07:43:00 Tuesday ET

Most agile lean enterprises often choose to cut costs strategically to make their respective business models fit for growth.

Most agile lean enterprises often choose to cut costs strategically to make their respective business models fit for growth. Vinay Couto, John Plansky,

+See More

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2020.

Andy Yeh Alpha

2020-02-02 10:31:00 Sunday ET

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2020.

Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implement

+See More

Calomiris and Haber delve into the comparative analysis of bank crises and politics in America, Britain, Canada, Mexico, and Brazil.

Dan Rochefort

2023-04-14 13:32:00 Friday ET

Calomiris and Haber delve into the comparative analysis of bank crises and politics in America, Britain, Canada, Mexico, and Brazil.

Calomiris and Haber delve into the comparative analysis of bank crises and politics in America, Britain, Canada, Mexico, and Brazil. Charles Calomiris an

+See More

Michael Bloomberg criticizes that the Trump administration's tax reform is a trillion dollar blunder.

Fiona Sydney

2017-12-09 08:37:00 Saturday ET

Michael Bloomberg criticizes that the Trump administration's tax reform is a trillion dollar blunder.

Michael Bloomberg, former NYC mayor and media entrepreneur, criticizes that the Trump administration's tax reform is a trillion dollar blunder because i

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

JPMorgan Chase CEO says President Trump has now awaken the animal spirits in U.S. stocks.

Dan Rochefort

2017-02-13 09:35:00 Monday ET

JPMorgan Chase CEO says President Trump has now awaken the animal spirits in U.S. stocks.

JPMorgan Chase CEO Jamie Dimon says President Trump has now awaken the *animal spirits* in the U.S. stock market. The key phrase, animal spirits, is the

+See More